Skip to main content

Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Publication ,  Other
Gupta, S; Halabi, S; Kemeny, G; Anand, M; Giannakakou, P; Nanus, DM; George, DJ; Gregory, SG; Armstrong, AJ
April 3, 2023

<p>Genomic-wide CNAs analysis in CTCs in the radium-223 trial. Top genomic gain (A) and loss (B) detected in the PROPHECY trial were independently validated in the radium-223 trial CTCs DNA (N=14 patients) study. Before radium-223 treatment, these patients were priorly treated with enza/abi.</p>

Duke Scholars

DOI

Publication Date

April 3, 2023
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, S., Halabi, S., Kemeny, G., Anand, M., Giannakakou, P., Nanus, D. M., … Armstrong, A. J. (2023). Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. https://doi.org/10.1158/1541-7786.22527284
Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527284.
Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, George DJ, Gregory SG, Armstrong AJ. Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 2023.

DOI

Publication Date

April 3, 2023